The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth
Cells, 2023 It is well established that Cholangiocarcioma (CCA) drug resistance plays a crucial role in the spread and survival of cancer cells.
Estanislao Peixoto +2 more
exaly +3 more sources
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury
Journal of Neuroinflammation, 2012 Background Emerging data implicate nicotinamide phosphoribosyl transferase (NAMPT) in the pathogenesis of cancer and inflammation. NAMPT inhibitors have proven beneficial in inflammatory animal models of arthritis and endotoxic shock as well as in ...
Salvatore Cuzzocrea +2 more
exaly +3 more sources
Frontiers in Oncology, 2022 Anaplastic meningioma is classified as a World Health Organization (WHO) grade III tumor and shows a strong tendency to recur. Although the incidence of anaplastic meningioma is low, the high rate of recurrence and death still makes treatment a challenge.
Yuxuan Deng +11 more
doaj +1 more source
Structural basis for resistance to diverse classes of NAMPT inhibitors. [PDF]
PLoS ONE, 2014 Inhibiting NAD biosynthesis by blocking the function of nicotinamide phosphoribosyl transferase (NAMPT) is an attractive therapeutic strategy for targeting tumor metabolism.
Weiru Wang +17 more
doaj +1 more source
Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression
Hepatology, EarlyView., 2022 Improved mitochondrial activity, due to the lack of methylation‐controlled J protein (MCJ), creates a specific microbiota signature that when transferred through cecal microbiota transplantation delays NASH progression by restoring the gut‐liver axis and enhancing hepatic fatty acid oxidation.
María Juárez‐Fernández +18 more
wiley +1 more source
NAD pool as an antitumor target against cancer stem cells in head and neck cancer
Journal of Experimental & Clinical Cancer Research, 2023 Summary Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors that affect different anatomical locations. Despite this heterogeneity, HNSCC treatment depends on the anatomical location, TNM stage and resectability of the tumor.
Lola E. Navas +10 more
doaj +1 more source
Journal of Hematology & Oncology, 2021 KPT-9274 is a phase 1 first-in-class dual PAK4/NAMPT inhibitor for solid tumor and non-Hodgkin’s lymphoma. It demonstrates pre-clinical efficacy toward a broad spectrum of acute myeloid leukemia (AML) subtypes by inhibiting NAMPT-dependent NAD ...
Shaneice Mitchell +8 more
doaj +1 more source
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. [PDF]
PLoS ONE, 2008 Nicotinamide phosphoribosyltransferase (NAMPT), also known as visfatin, is the rate-limiting enzyme in the salvage pathway of NAD biosynthesis from nicotinamide.
Nathalie Busso +8 more
doaj +1 more source
Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells. [PDF]
PLoS ONE, 2013 A number of cancers show increased expression of Nicotinamide phosphoribosyl transferase (Nampt). However, the mechanism through which Nampt is upregulated is unclear.
Chenpeng Zhang, Jinlu Tong, Gang Huang
doaj +1 more source
Nampt Expression Decreases Age-Related Senescence in Rat Bone Marrow Mesenchymal Stem Cells by Targeting Sirt1. [PDF]
PLoS ONE, 2017 Senescence restricts the development of applications involving mesenchymal stem cells (MSCs) in research fields, such as tissue engineering, and stem cell therapeutic strategies.
Cao Ma +7 more
doaj +1 more source